23 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
for infertility treatments. According to the Centers for Disease Control and the European Society of Human Reproduction and Embryology, IVF represents … by fertilization and early embryo development in the laboratory before transfer of the embryos into the womb. According to the European Society of Human
6-K
EX-99.1
OBSVF
ObsEva SA
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
pharmaceutical company based on the management philosophy “contributing to society through high-quality, innovative pharmaceutical products … ” and “serving society through our employees.” As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide
6-K
EX-99.1
OBSVF
ObsEva SA
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
on the management philosophy “contributing to society through high-quality, innovative pharmaceutical products” and “serving society through our
6-K
EX-99.1
OBSVF
ObsEva SA
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
on the management philosophy “contributing to society through high-quality, innovative pharmaceutical products” and “serving society through our employees
6-K
EX-99.1
OBSVF
ObsEva SA
22 Mar 22
Current report (foreign)
7:28am
www.ObsEva.com
About Kissei Pharmaceutical Co., Ltd.
Kissei is a Japanese pharmaceutical company based on the management philosophy “contributing to society … through high-quality, innovative pharmaceutical products” and “serving society through our employees.” As a strong R&D-oriented corporation
6-K
EX-99.1
869976g6fec3oe7y6
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
6-K
EX-99.1
bnncuwf02b i6x
4 Feb 22
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral
4:37pm
6-K
EX-99.1
z21k07k vuprls4o
6 Jan 22
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
6:30am
6-K
EX-99.1
gcyl 8ckz8fxisdo2ec
10 Dec 21
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
8:12am
6-K
EX-99.2
mj24v1p6py6vyoyqt
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K
EX-99.2
42wp6x0yni40biyyt558
5 Aug 21
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
EX-99.3
gisto
7 Nov 19
Current report (foreign)
9:11am
6-K
EX-99.3
e13gc7jijmw
7 Aug 19
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
EX-99.3
qqkt6hrvth8ll0htrl1h
8 Nov 18
Index to Unaudited Condensed Consolidated Financial Statements
9:28am
6-K
j9ne n3ef
9 Oct 18
Current report (foreign)
4:42pm